Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 19

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 19
---
 or at all.

Federal, state and foreign statutes allow courts, under specific circumstances, to void the notes and the guarantees.

The issuance of the notes and the guarantees may be subject to review under federal, state and foreign fraudulent transfer and conveyance statutes. While the relevant laws may vary from jurisdiction to jurisdiction, under such laws the issuance or guarantees of the notes would generally be a fraudulent conveyance if (1) AMS Europe issued the notes or Boston Scientific provided the guarantees with the actual intent of hindering, delaying or defrauding creditors or (2) AMS Europe or Boston Scientific, as applicable, received less than reasonably equivalent value or fair consideration in return for issuing the notes or guarantees, as applicable, and, in the case of (2) only, one of the following is also true:

•

AMS Europe or Boston Scientific was insolvent or rendered insolvent by reason of the incurrence of the indebtedness;

•

the issuance of the notes or the guarantees left AMS Europe or Boston Scientific, respectively, with an unreasonably small amount of capital to carry on its business; or

•

AMS Europe or Boston Scientific intended to, or believed that it would, incur debts beyond its ability to pay as they mature or become due.

If a court were to find that the issuance of the notes or the guarantees was a fraudulent conveyance, the court could void the payment obligations under the notes or the guarantees or subordinate the notes or the guarantees to presently existing and future indebtedness of AMS Europe or Boston Scientific, or require the holders of the notes to repay any amounts.

Generally, an entity would be considered insolvent if at the time it incurred indebtedness:

•

the sum of its debts, including contingent liabilities, was greater than the fair saleable value of all its assets;

<div align='center'>S-8</div>

TABLE OF CONTENTS

•

the present fair saleable value of its assets was less than the amount that would be required to pay its probable liability on its existing debts and liabilities, including contingent liabilities, as they become absolute and mature; or

•

it could not pay its debts as they become due.

We cannot be certain as to the standards a court would use to determine whether or not AMS Europe or Boston Scientific was solvent at the relevant time, or regardless of the standard that a court uses, that the issuance of the notes or the guarantees would not be subordinated to any of Boston Scientific’s other debt.

Holders of the notes may be subject to the effects of foreign currency exchange rate fluctuations, as well